Revenue from commercial sale of products relates to sale of SKYTROFA® (lonapegsomatropin-tcgd) on the U.S. market, which is sold to specialty pharmacies and a specialty distributor (“commercial customers”). Customer payment terms are typically 30 days from the transaction date. SKYTROFA was approved by the U.S. Food and Drug Administration in August 2021, and the Company began shipping products to commercial customers in the fourth quarter of 2021.

Other revenue is generated primarily from three license agreements, which were entered into in 2018. The licenses grant VISEN Pharmaceuticals exclusive rights to develop and commercialize TransCon hGH, TransCon PTH and TransCon CNP in Greater China.


	Three Months Ended September 30,				Nine Months Ended September 30,
	2022		2021		2022		2021
	(EUR’000)				(EUR’000)
Revenue from external customers
Commercial sale of products		12,252		—		18,575		—
Rendering of services		2,401		203		3,385		599
Sale of clinical supply		—		316		4,405		533
Licenses		637		594		1,913		1,749
Total revenue from external customers		15,290		1,113		28,278		2,881
Attributable to
Commercial customers		12,252		—		18,575		—
Collaboration partners and license agreements		3,038		1,113		9,703		2,881
Total revenue from external customers		15,290		1,113		28,278		2,881
Specified by timing of recognition
Recognized over time		2,401		203		3,385		599
Recognized at a point in time		12,889		910		24,893		2,282
Total revenue from external customers		15,290		1,113		28,278		2,881
Revenue by geographical location
Europe		151		—		426		—
North America		12,889		702		24,424		2,076
China		2,250		411		3,428		805
Total revenue from external customers		15,290		1,113		28,278		2,881